搜索
InflaRx NV
IFRX添加自选
2.500USD
+0.030+1.21%
收盘 05/18, 16:00（美东）报价延迟15分钟
368.23M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.21%
5天
0.00%
1月
+57.23%
6月
+96.85%
今年开始到现在
+147.52%
1年
+50.60%
TradingKey InflaRx NV股票评分
单位: USD 更新时间: 2026-05-18操作建议
InflaRx NV当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名93/381位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.43。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
InflaRx NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
InflaRx NV亮点
亮点风险
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
业绩增长期
公司处于发展阶段，最新年度总收入25.31K美元
估值低估
公司最新PE估值-4.63，处于3年历史低位
机构减仓
最新机构持股19.59M股，环比减少19.00%
史蒂文·科恩持仓
明星投资者史蒂文·科恩持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率3.19
分析师目标
根据
8
位分析师
买入
评级
7.429
目标均价
+200.75%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
InflaRx NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
InflaRx NV简介
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
公司代码IFRX
公司InflaRx NV
CEORiedemann (Niels C)
网址https://www.inflarx.de/
相关品种
